Clinical trial
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus…
NCT00479401 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00479401 |
|---|---|
| Title | Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients |
| Official title | A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD). |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Early Parkinson Disease (Early PD) |
| Intervention type | Drug |
| Interventions | Pramipexol Extended Release, Pramipexol Immediate Release, Placebo |
| Enrollment | 539 |
| Start date | May 1, 2007 |
| Primary completion | Nov 1, 2008 |
| First posted | May 28, 2007 |
| Last update posted | Jul 17, 2014 |
| Countries | Argentina, Austria, Czechia, Finland, Germany, Hungary, India, Japan, Malaysia, Russia, Slovakia, Taiwan and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: